Tumor-induced activation of β-catenin in DCs has been shown to impair their function in mediating anti-tumor CD8 T-cell responses [24,25,26,27], further supporting β-catenin as a critical negative regulator of DC function [28,29]. This evidence concerns the gene CD8A and neoplasm.